Staphylococcus aureus serine protease-like protein B elicits a type 1/type 2 immune response in atopic dermatitis patients
By
Rebecca Pospich
Goran Abdurrahman
Tatjana Honstein
Maria Nordengrün
Stephan Traidl
Gabriele Begemann
Petra Kienlin
Thomas Werfel
Barbara M. Bröker
Lennart M. Roesner
June 4, 2026
Clinical Scorecard: Staphylococcus aureus Serine Protease-Like Protein B Induces Type 1 and Type 2 Immune Responses in Patients with Atopic Dermatitis
At a Glance
Category Detail
Condition Atopic Dermatitis (AD) Key Mechanisms Involvement of Staphylococcus aureus serine proteases in immune response modulation. Target Population Patients with Atopic Dermatitis, including children and adults. Care Setting Dermatology and Allergy clinics.
Key Highlights
Elevated IgE levels specific to Staphylococcus aureus serine proteases in AD patients. SplB induces T cell activation and cytokine secretion in both AD patients and healthy controls. Clonal propagation of SplB-specific T cells found in lesional skin of AD patients. Type 1 and type 2 cytokine production observed in SplB-specific T helper cells. Guideline-Based Recommendations
Diagnosis
Diagnosis of AD based on Hanifin and Rajka criteria. Assessment of disease severity using SCORAD score. Management
Consideration of immune response to S. aureus in treatment strategies. Monitoring & Follow-up
Monitoring IgE levels and T cell responses in patients with AD. Risks
Increased disease severity associated with S. aureus colonization. Patient & Prescribing Data
Adults with mild-to-severe Atopic Dermatitis.
Avoidance of systemic corticosteroids, immunosuppressants, and allergen-specific immunotherapy prior to study.
Clinical Best Practices
Regular assessment of skin lesions and immune responses in AD patients. Incorporation of microbiome considerations in AD management. Related Resources & Content
